Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

A study to be published in the latest issue of The Cochrane Library and led by researchers at the University of Edinburgh and supported by colleagues at the Peninsula Dental School, the University of Ottawa and UCL Eastman Dental Institute, suggests that the treatment of serious gum (periodontal) disease in diabetics with Type 2 diabetes may lower their blood sugar levels.

12 May 2010

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes who have preexisting gum disease.

12 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

People with family history of diabetes gain more weight

In the first study of its type, Australian researchers have shown that healthy people with a genetic predisposition to Type 2 diabetes gain more weight overeating over the short term than their non-genetically-prone counterparts.

11 May 2010

Genetic link to risk for diabetes and weight gain: New study

A recent study published in the international journal Diabetologia showed that Australians who eat too many high fat snacks tend to put on more weight if they have someone in their family with diabetes.

10 May 2010

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has achieved enrolled of over 400 subjects in its pivotal global Phase III study of its flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product designed to replace prandial injections of insulin.

10 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Findings may help develop a new class of drugs for diabetes

More than half a century after researchers identified a promising way to treat diabetes based on blocking the breakdown of insulin in the body, a research team led by a scientist at the Mayo Clinic campus in Florida have developed potent molecules that can do just that.

10 May 2010

Insulin can help reduce risk of type 2 diabetes

Recent decades have seen a huge increase in type 2 diabetes and cardiovascular disease. This is a result of people being less active and eating fattier diets, which can lead to obesity and, in turn, diabetes.

10 May 2010

Halozyme Therapeutics first-quarter net loss decreases to $11.8 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

New documentary film reveals effective alternative therapies for health problems

Soft Touch Chiropractic and Acupuncture will be hosting the following free movie screenings at their wellness center located at 19474 Rinaldi St. Northridge, CA 91326.

7 May 2010

Imprinted genes may be the root cause of gender specific diseases, says study

Pregnancy places competing demands on a mother's physiology: Her body wants to produce a strong healthy baby but not at the expense of her own health. Some of the genes that she passes on to her child therefore try to protect her own body from excessive demands from her child.

7 May 2010

Tel Aviv researchers develop microscope-based cell scanner to speed research into fat-busting drugs

Anglers rely on fish finders to help them locate the big catch. Now Tel Aviv University researchers in tissue engineering have developed a "fat finder" that can help scientists accelerate their research into new fat-melting drugs.

7 May 2010

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801.

7 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

New study shows single night of partial sleep deprivation can induce insulin resistance

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism, just one night of short sleep duration can induce insulin resistance, a component of type 2 diabetes.

6 May 2010

Whole grain barley products with low glycemic response provide favourable metabolic benefits

Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.

6 May 2010

ViaCyte granted three new U.S. patents

ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents.

6 May 2010

Obesity epidemic may be flattening out - still much to be done

The prevalence of childhood obesity might be stabilising in developed countries, but there is still much to be done to combat this major threat to health, according to a Seminar published on Online First and in an upcoming issue of The Lancet.

6 May 2010

Insulin News and Research

Further Reading

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

Transition Therapeutics reports increased revenue in third-quarter 2010

People with family history of diabetes gain more weight

Genetic link to risk for diabetes and weight gain: New study

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Findings may help develop a new class of drugs for diabetes

Insulin can help reduce risk of type 2 diabetes

Halozyme Therapeutics first-quarter net loss decreases to $11.8 million

New documentary film reveals effective alternative therapies for health problems

Imprinted genes may be the root cause of gender specific diseases, says study

Tel Aviv researchers develop microscope-based cell scanner to speed research into fat-busting drugs

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

New study shows single night of partial sleep deprivation can induce insulin resistance

Whole grain barley products with low glycemic response provide favourable metabolic benefits

ViaCyte granted three new U.S. patents

Obesity epidemic may be flattening out - still much to be done

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News